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Abstract. A novel methodology for the synthesis of sulfo- and oxy-modified amino acid analogues of  
arginine (Arg) has been developed using both conventional and polymer assisted synthesis from ready 
available amino acid precursor. Introduction of guanidine group was made also by the MWA synthesis. 
The in vitro inhibitory effect of the amino acid analogues on the growth of murine erythroleukemia cells, 
clone F4N in culture was also studied. (doi: 10.5562/cca1780)  
Keywords: canavanine, mimetics, polymer assisted synthesis, micro wave assisted synthesis, erythro-
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INTRODUCTION 
As the building blocks of peptides and proteins, amino 
acids are vitally important biochemical species. A de-
tailed knowledge of their chemical properties is essen-
tial to understanding the complex interplay between 
amino acid structure and biological function.  
One of the most prominent members of coded 
amino acids is arginine (Arg), which has been intensive-
ly studied with the respect to biological properties and 
as a building block in peptide chemistry.1 Arginine, 
guanidine-containing amino acid, plays an important 
role in biologically active proteins and peptides and is 
involved in many important physiological and patho-
physiological processes.2–4 The guanidino group of Arg 
is the important detail of its biological specificity, a 
group with a high pK that is positively charged at all 
biologically relevant pH values. A highly basic guanidi-
no moiety incorporated in enzyme inhibitors or receptor 
antagonists is however, often associated with low selec-
tively, excreted rapidly, or do not pass biological mem-
branes resulting in a poor bioavailability.  
A significant effort has therefore been focused on 
the design and preparation of arginine analogues which 
possess reduced basicity, resulting in increased stability 
towards enzymatic degradation.5  
In this context, we have focused on the design and 
synthesis of unnatural amino acids and their derivati- 
ves, containing a basic functionality (oxy- and sulfo-
guanidino), as structural analogues of arginine (Arg) 
and canavanine (Cav).6–9 Their effects on the growth of 
microorganisms, model plant systems, cultured tumor 
cells and their antitumor activity in vivo have been eva-
luated.10,11 In addition to their interesting biological 
properties, these unnatural amino acids were incorpo-
rated into biologically active peptidomimetics.12–15  
Consequently, these studies emphasize the need of 
milder and more practical conditions for preparation of 
these arginine analogues. 
In this article we report optimization of the synthe-  
sis of previously described oxy- and sulfo-analogues of 
arginine.8,9,16 The optimization strategy included a poly-
mer assisted synthesis (PAS) methodology, which com-
bines advantages of traditional solution phase chemistry 
with application of polymeric agents. Moreover, the intro-
duction of guanidine group was made also by the micro 
wave assisted (MWA) synthesis. This approach led to the 
desired compounds in a high throughput manner, in suffi-
cient purity, without additional purification steps. 
The in vitro inhibitory effect of the amino acid 
analogues on the growth of murine erythroleukemia 
cells, clone F4N in culture was also studied.  
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EXPERIMENTAL 
Materials and Methods 
All chemicals were of analytical grade. All anhydrous 
solvents were obtained commercially (Fluka) and used 
directly. HPLC-grade acetonitrile and MeOH were 
purchased from Merck. The Wang resin (100–200 
mesh, 0.5–1.3 mmol g–1) was obtained from Nava-
biochem (Switzerland). MWA synthesis was per-
formed on Microwave oven, Model MARS-X, CEM 
Corporation. Analytical TLC was performed on Merck 
silica gel (60F254) plates (0.25 mm) using of the fol-
lowing solvent systems: A: V(chloroform) : V(metha-
nol) : V(water) = 80 : 30 : 5; B: V(benzene) : V(acetone) :  
V(acetic acid) = 100 : 50 :2; C: V(chloroform) : V(metha-
nol) : V(acetic acid) = 95 :5 : 5. Visualization was done 
with either UV, ninhydrin or a chlorine tolidine reagent. 
Melting points were determined on a Büchi melting 
point apparatus and are uncorrected. Optical rotation 
was measured with a Perkin-Elmer Model 141 polari-
meter. IR spectra were recorded on Specord-71-IR 
(Zeiss) or Bruker 113V spectrophotometers. 1H NMR 
spectra were recorded on Bruker WM-250 and Avance 
DRX-250 (250 MHz) spectrometers. Mass spectra were 
recorded on an Fissons-Triple Quadrupol-ES mass spec-
trometer. HPLC analyses were performed on Agilent 
Technologies HP 1100 and Dionex, Ultimate® 3000 LC 
instruments, using a Beckman UltrasphereTM RPC18 
(250 × 4.6 mm, 5 μm) and ZIC®-HILIC (100 × 4.6 mm, 
5 μm) columns. Chiral analyses were performed on 
micro-HPLC using microbore column packed with the 
macrocyclic antibiotic Ristocetin A immobilized on 3.5 
m silica gel (100 × 1 mm) from ASTEC (Whippany, 
NJ, USA). Dulbecco's modified Eagle medium was 




To the solution of Z-Ser-OBzl (1.2 g, 4 mmol) in DCM 
(10 ml) at –10 °C DIPEA (13.79 ml, 80 mmol) was 
added, and after that Mes-Cl (0.62 ml, 8 mmol) drop-
wise. The reaction mixture was stirred for 2 hours at 
room temperature. Product (2) was obtained without 
further purification after evaporation of the solution in 
vacuo (1.6 g ,70 %) and it was used for the next step.  
 
Z-CH(CH2SO3H)-OBzl (3) 
Method I: 2 (0.4 g, 1 mmol) was suspended in water (2 
ml) and a solution of Na2SO3 (0.6 g, 5 mmol) in water 
(5 ml) was added. The reaction mixture was stirred at 
room temperature for 24 hours. After acidification a 
new product (3) was obtained as white crystals from the 
reaction mixture. It was filtered out, washed with water 
and dried in vacuo (0.3 g, 75 % yield). 
Method II. The same as in method I, but with the fol-
lowing conditions at microwave irradiation (300 W),  
1 min to 40 °C, hold 5 min (0.35 g, 87 % yield). 
 
Z-Cys(SO2Cl)-OBzl (4) 
To the solution of 3 (0.2 g, 0.5 mmol) in DCM (5 ml) at 
–5 °C, SOCl2 (0.18 ml, 2.5 mmol) was added dropwise. 
Reaction mixture was stirred at 0 °C for 2 hours. DCM 
was evaporated in vacuo and 3 was obtained as a white 
solid (0.11 g, 57 % yield).  
 
Z-NsArg(Boc)-OBzl (5) 
To the mixture of mono-Boc-guanidine (1g, 6.3 mmol) 
and Et3N (0.88 ml, 6.3 mmol) in DMF at 0 °C a solution 
of Z-Cys(SO2Cl)-OBzl (1.3 g, 3.2 mmol) in DMF was 
added dropwise. The reaction mixture was stirred at room 
temperature for 24 h and then hot water was added.  
The resulting oil was taken up with EtOAc and organic 
layer was washed subsequently with 5 % NaHCO3, 5 % 
NaHSO4 and brine. EtOAc was dried over Na2SO4, 
evaporated under reduced pressure and the resulting 
product was recrystalized from EtOAc/light petroleum 
(0.9 g, 52 % yield). 22D[ ] 2.6 α     (c = 1, DMF); Rf (A) 
0.98; Rf (B) 0.76; MS-ES, m/z: 535[M
+] C24H30N4O8S 
(534.595); 1H-NMR (CDCl3) δ/ppm: 8.0 (m, 2H, NH), 
7.1 (m, 10H, Ar), 5.3 (m, 4H, CH2Ph), 4.4 (m, 1H, CH), 
4.0 (m, 2H, CH2SO2), 1.4 (s, 9H, t-Bu), 2.0 (s, 2H, Gu). 
 
Z-NsArg(Boc)-OH (6) 
4 (0.3 g, 0.6 mmol) was dissolved in a mixture of dio-
xane and water (volume ratio = 1:1) and 1M solution of 
NaOH was added dropwise until hydrolysis completed. 
Dioxane was evaporated in vacuo and the aqueous solu-
tion was acidified to pH = 3 and extracted with EtOAc 
(3 × 10 ml). The combined organic layers were washed 
with brine to pH = 7 and dried over Na2SO4. EtOAc was 
evaporated under reduced pressure and the product was 
recrystalized from EtOH to obtain 0.18 g (74 % yield). 
C17H24N4O8S (444.471); Rf (B) 0.52, Rf (C) 0.30;  
1H-NMR (CDCl3) δ/ppm: 11.0 (s, 1H, OH ), 8.0 (m, 
2H, NH), 7.2 (m, 5H, Ar), 5.4 (m, 2H, CH2Ph), 4.5 (m, 




5 (0.1 g, 0.2 mmol) was dissolved in DCM and mixture 
of HBr and CH3COOH (0.5 ml) was added. Deprotec-
tion was carried out for 1 hour at room temperature and 
the solvent was evaporated in vacuo. The solid residue was 
recrystalized from EtOEt to obtain 0.04 g (97 % yield). 
22
D[ ] 14.5 α     (c = 1, H2O); MS-ES, m/z: 284[M
+] 
C4H10N4O4S (283.152); 
1H-NMR (CDCl3) δ/ppm: 11.0 
(s, 1H, OH), 3.9 (d, 2H, CH2SO2), 3.5 (m, 1H, CH), 2.0 




D[ ] 24.3 α     (c = 1, H2O); MS-ES, m/z: 163 [M
+] 
C4H10N4O3 (162.15); 
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anal. calcd. mass fraction (w/%) of N is 34.55, found 
34.6; IR (KBr) 1 max / cmν
 : 3420, 3315, 3033, 1755, 
1687 (C=N), 1610, 1312, 748; 1H-NMR (D2O) δ/ppm: 
7.58 (s(br), 4H, guanidino-NH), 4.38 (m, 1H, α-CH), 
2.20 (m, 2H, β-CH2). 
 
Z-Ser(OPhth)-OBzl (8) 
Method I. To the solution of 2 (0.8 g, 2 mmol) and  
N-hydroxyphthalimide (0.65 g, 8 mmol) in THF (20 ml) 
DBU (0.6 ml, 4 mmol) was added. The reaction mixture 
was stirred at room temperature for 24 hours. THF was 
evaporated in vacuo and the residue was dissolved in 
DCM (30 ml) and was washed with water to pH = 7. 
The organic layer was dried over Na2SO4, filtered out and 
CHCl3 was evaporated in vacuo to obtain 0.41 g (89 % 
yield) of 7. 22D[ ] 18.3 α     (c = 1, DMF); MS-ES, m/z: 
583 [M+] C37H30N2O5 (582.66); Rf (B) 0.81, Rf (C) 0.75; 
1H-NMR (CDCl3) δ/ppm: 8.1 (m, 2H, Phth), 7.7 (m, 
2H, Phth), 7.2 (m, 5H, Ar), 7.14–7.06 (m, 15H, Trt), 5.3 
(s, 2H, CH2), 4.0 (d, 2H, CH2O), 3.5 (m, 1H, CH).  
Method II. The same as in method I, but with the fol-
lowing conditions at microwave irradiation (300 W), 
1 min to 40 °C, hold 5 min (0.42 g, 92 % yield).  
 
Z-NCan-OBzl (9) 
7 (0.4 g, 0.8 mmol) was dissolved in EtOH (4 ml) and 
N2H4·H2O (0.5 ml) was added. The mixture was stirred 
at room temperature for 24 hours and EtOH was evapo-
rated in vacuo. The residue was recrystalized from mix-
ture of EtOAc and petroleum ether to obtain 0.24 g (85 % 
yield) of 8. C18H20N2O5 (344.37); Rf (B) 0,74; Rf (C) 
0,61; 1H-NMR (CDCl3) δ/ppm: 9.0 (s, 2H, NH2), 8.1  
(d, 1H, NH), 7.1 (m, 10H, Ar), 5.3 (s, 4H, CH2), 4.51  
(m, 1H, CH), 4.1 (d, 2H, CH2O). 
 
Z-NCav(Boc)2-OBzl (10) 
To the solution of 1H-pyrazol-1(N,N’-bis-Boc)-carbox- 
amidine (0.55 g, 1.6 mmol) and DIPEA (0.7 ml, 4 
mmol) in CH3CN (4 ml) at room temperature, 8 (0.57 g, 
1.6 mmol) was added. The mixture was stirred for 24 
hours at room temperature. The solvent was evaporated 
in vacuo and the residue was dissolved in EtOAc (20 ml) 
and was washed subsequently with 5 % HCl (2×10 ml), 
brine and was dried over Na2SO4. EtOAc was evapo-
rated in vacuo and the resulting product was recrysta-
lized from mixture of EtOAc and hexane to obtain 0.37 
g (42 % yield). C29H38N4O9 (586.65); Rf (B) 0.9; Rf (C) 
0.91; 1H-NMR (CDCl3) δ/ppm: 8.0 (d, 3H, NH), 7.2  
(m, 10H, Ar), 5.4 (s, 4H, CH2), 4.51 (m, 1H, CH), 4.1  
(d, 2H, CH2O), 1.4 (s, 18H, t-Bu). 
 
Z-NCav(Boc)2-OH (11) 
9 (0.29 g, 0.6 mmol) was dissolved in a mixture of dio-
xane and water (volume ratio = 1:1) and 1M solution of 
NaOH was added dropwise until the hydrolysis was 
complete. Dioxane was evaporated in vacuo and the 
aqueous solution was acidified to pH = 3 and extracted 
with EtOAc (3×10 ml). The combined organic layers 
were washed with brine to pH = 7 and dried over 
Na2SO4. EtOAc was evaporated under reduced pressure 
and the product was recrystalized from EtOH to obtain 
0.18 g (76 % yield). 
 
NCav (12) 
10 (0.15 g, 0.3 mmol) was dissolved in DCM and mix-
ture of HBr and CH3COOH (0.5 ml) was added. Depro-
tection was carried out for 1 hour at room temperature 
and the solvent was evaporated in vacuo. The solid 
residue was recrystalized from EtOEt to obtain 0.047 g 
(96 % yield). 22D[ ] 24.3 α     (c = 1, H2O); MS-ES, m/z: 
163 [M+] C4H10N4O3 (162.15); anal. calcd. mass frac-
tion (w/%) of N is 34.55, found 34.6; IR (KBr) 
1
 max / cmν
 : 3420, 3315, 3033, 1755, 1687 (C=N), 1610, 
1312, 748; 1H-NMR (D2O) δ/ppm: 7.58 (s(br), 4H, gua-
nidino-NH), 4.38 (m, 1H, -CH), 2.20 (m, 2H, -CH2). 
 
Boc-Ser-Wang-Resin (13) 
In a round bottom flask the resin was suspended in 7 ml 
of mixture of CH2Cl2 and DMF (volume ratio = 9:1). In 
a separate flask, Boc-Ser (12) was dissolved in a mini-
mum amount of DMF (4 ml). The same equivalence of 
HOBt was added. The mixture was stirred until the 
HOBt was dissolved. This solution was added to the 
resin. In a separate flask Et3N was dissolved in a mini-
mum amount of DMF (1 ml). HBTU was added to the 
resin mixture then the DMAP solution was added. The 
mixture was shaken for 2 hours at room temperature. 
The resin was filtered and washed 3 times with DMF, 
then 3 times with DCM, and finally 3 times with metha-
nol. In each wash, enough solvent was used to slurry the 
resin. After the final methanol wash, the resin was dried 
in vacuo to a constant weight. The substitution of the 
resin can be estimated from the weight gain of the resin. 
 
Boc-Ser(OPhth)-Resin (14) 
Method I. Boc-Ser-Resin (0.25 g, 0.18 mmol) was sus-
pended in DMF (5 ml) and TPP (0.12 g, 0.45 mmol) and 
N-hydroxyphthalimide (0.06 g, 0.36 mmol) were added 
subsequently. DEAD (0.08 ml, 0.45 mmol) was added 
and the mixture was shaken for 2 hours at room temper-
ature. The resin was filtered and washed 5 times with 
DMF. 
Method II. The same as in method I, but with the fol-
lowing conditions at microwave irradiation (300 W),  
(1 min to 40 °C, 4×30 s hold). 
 
Boc-NCan-Resin (15) 
14 (0.95 g, 2 mmol) and N2H4·H2O (2 ml) were sus-
pended in EtOH (10 ml). The mixture was shaken for 2 
hours at room temperature. The resin was filtered and 
washed 3 times with EtOH and 3 times with DMF. 
 
Boc-NCav(Boc)2-Resin (16) 
Method I. The solution of 1H-pyrazol-1(N,N’-bis-Boc)-
carboxamidine (0.55 g, 1.6 mmol) and DIPEA (0.7 ml, 
4 mmol) in CH3CN (4 ml) was added at room tempera-
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ture to 15. The mixture was shaken for 24 hours at room 
temperature. The resin was filtered and washed 3 times 
with CH3CN and 3 times with DMF. 
Method II. The same as in method I, but with the fol-
lowing conditions at microwave irradiation (300W), 
1 min to 40 °C, hold 5 min. 
 
NCav (11) 
Cleavage of 11 from the resin was achieved with acidic 
hydrolysis with 5 ml of 95 % TFA for 30 min. The resin 
was filtered out and the solvent was evaporated in vacuo. 
NCav was obtained as a white solid (0.03 g, 53 % yield). 
 
HPLC-characterization of Reaction Products 7 and 12 
All samples were prepared in a concentration of 1 mg 
ml–1 and dissolved in the mobile phase. Mobile phases 
were degassed for 10 min by helium 5.0. 
 
Determination of Purity of Crude Products 7 and 12 
HPLC analysis of the products were performed on a 
column Beckman UltrasphereTM RPC18 (250×4.6 mm,  
5 μm) with a mobile phase: mixture of 0.01 M K2HPO4 
(pH = 2.5) and acetonitrile (volume ratio = 80 : 20) over 
30 min at a flow rate of 0.5 ml min–1. Detection was 
performed at 230 nm. 
Sample analysis carried out on column ZIC®-
HILIC (100×4.6 mm, 5μm) with a mobile phase: mix-
ture of 0.05 M CH3COONH4 (pH = 6.8) and acetonitrile 
(volume ratio = 50 : 50) for NCav, and mobile phase: 
mixture of 0.005 M CH3COONH4 (pH = 6.8) and ace-
tonitrile (volume ratio = 20 : 80)for NsArg, respectively 
at a flow rate 0.5 ml min–1. Detection was performed at 
230 and 254 nm. 
 
Determination of Enantiomeric Purity of the Crude 
Products 7 and 12 
Micro-HPLC analysis of the products were performed 
on a column packed with the macrocyclic antibiotic 
Ristocetin A immobilized on 3.5 m silica gel (100×1 
mm) with a mobile phase: mixture of 0.1 % TEAA in 
water (pH = 6.9) and methanol (volume ratio = 80 : 20) 
at a flow rate 30 μl min–1. Detection was performed at 
208 nm. 
 
Incubation with Drugs and In Vitro Cytotoxicity Test 
Murine erythroleukemia cells, clone F4N17 were cul-
tured in Dulbecco's modified Eagle medium supple-
mented with 10 % calf serum, under a 5 % CO2 atmos-
phere at 37 °C, and passed every day at a concentration 
of 5×105 cells ml–1. 
The inhibitors were dissolved immediately before 
use in DMSO to obtain stock solutions of different con-
centrations. Each of these solutions was used at 1 % 
concentration in the experiments with F4N cells. Con-
trol samples were incubated in the presence of 1 % 
DMSO. The final concentration of DMSO in the me-
dium did not affect cell growth. 
Exponentially growing cells (0.5×106 cells ml–1) 
were incubated in triplicate with increasing concentra-
tions of the test complexes in 96-well microtiter plates. 
After 24, 48 and 72 h of drug treatment, the cells were 
counted hemocytometrically. The number of dead cells 
was determined by staining with trypan blue. The mean 
of triplicate determinations of three independent expe-
riments was calculated. The 50 % inhibitory dose 
(IC50) was defined as drug concentration that reduces 
the number of living cells by 50 %. 
 
RESULTS AND DISCUSSION 
We have recently reported a general synthetic route to 
sulfo- and oxo-analogues of Arg.8,9 
Scheme 1. Synthesis of NsArg and NCav. Reagents and con-
ditions. 
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As outlined at the Scheme 1, sulfo- and oxo-
analogues of Arg (Figure 1) were prepared for the first 
time starting from the same key compound Ser. The first 
steps of this route were common for obtaining the mesy-
lated fully protected Ser (2) and after that we prepared 
NCav (12) and NsArg (7) analogues.  
For the preparation of NsArg (7) we applied a new 
approach – synthesis of sulfonyl chloride (4) via sulfon-
ic acid18 (3) by conventional synthesis in solution or in 
conditions of microwave irradiation. In the second case 
the reaction time was shortened from 24 hours to 5 
minutes. All other steps of this synthetic scheme have 
been previously described. 
NCav (12) was synthesized by using two different 
approaches. The first was based on conventional me-
thods in solution (Scheme 1), the second – on solid 
phase organic synthesis (Scheme 2). In some steps of 
both synthetic schemes we applied for first time micro-
wave irradiation. In conditions of MWA, SPS on the 
first and second stages reaction was carried out at 40 
degrees and an irradiation time of totally 2 minutes. 
Introduction of guanidine group was made also in the 
MWA synthesis at 40 degrees and irradiation time of 5 
minutes. 
The synthesis of the hydrazide derivatives of 
NsArg and NCav (Figure 1) has been described pre-
viously.8,9 Both of the hydrazides, NsArg-
CONHNHC6H5 (18) and NCav-CONHNHC6H5 (19) 
were prepared by a condensation reaction of the corres-
ponding di-protected compound with the Boc-
NHNHC6H5 in the presence of DIPEA, using TBTU 
reagent. The condensation method we have applied 
afforded high purity products and column chromatogra-
phy purification was not required. Moreover, it should 
be noted that under the mild conditions of the synthesis, 
undesirable side processes, including racemization, did 
not take place. Cleavage of the protecting Boc-group 
was achieved by ethyl acetate saturated by ethyl acetate 
saturated anhydrous HCI (mixture of 1.5 M HCl and 
EtOAC), or mixture of TFA and anisole (volume ratio = 
9 : 1) in 95–98 % yields. 
In conjunction with these synthesis routes, analyt-
ical methods are required to monitor the chemical and 
enantiomeric purity of the formed products. Using op-
timized conditions described above, excellent purity 
obtained of 7 (98 %) and 12 (96 %) in the crude HPLC-
chromatograms (Figures 2 and 3). For most applications 
the purity of these products will be sufficient. 
To determine whether the MWA conditions re-
sulted in racemization at the α-amino center, 7 and 12 
were evaluated for enantiomeric purity. As several UAA 
were successfully analyzed by us using macrocyclic 
antibiotic phases,19 it was decided to adapt this well 
established method for the chiral analysis of NCav and 
NsArg. 
The resulting chromatograms did not show detect-
 
Scheme 2. Synthesis of NCav on solid support. Reagents and
conditions. 
 
Figure 1. Structures of NsArg, NCav and their phenylhy-
drazides.  
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able diastereomeric contamination, indicating that the ee 
value of 12 is > 98.9 % (Figure 4). 
The elemental analysis and spectral data con-
firmed the structures of the sulfo- and oxo-analogues of 
Arg shown in Figure 1, and were in accordance with the 
data reported in our previous papers.8,9 
 
Cytotoxic Effect 
The cytotoxicity of NCav, NCav-CONHNHC6H5, 
NsArg, NsArg-CONHNHC6H5 in F4N cells was ex-
amined using cell-growth assay. The growth-inhibitory 
effects of 24, 48 and 72 h incubation of the cells with 
the drugs are expressed by IC50 values (Table 1). Clear 
differences in the cell growth were observed after 48 
and 72 h of incubation. IC50 values of NCav were 
found to be 8 and 3.2 mmol dm–3 after 48 and 72 h in-
cubation respectively, while those of NCav-CONH-
NHC6H5 were 2.5 and 1.3. The second compound 
proved to be 3 times more cytotoxic than NCav. Similar 
results were obtained for NsArg and its phenylhydrazide 
derivative NsArg-CONHNHC6H5. The concentrations 
of NsArg reducing the number of living cells by 50 % 
ranged from 4 to 2.4 mmol dm–3 for the different times 
of treatment, while those of NsArg-CONHNHC6H5 
ranged from 4.6 to 0.8 mmol dm–3. These results con-
Figure 2. HPLC-chromatogram of crude NCav. Column: Beck-
man UltrasphereTM RPC18 (250 × 4.6 mm); mobile phase: mix-
ture of 0.01 M K2HPO4 (pH = 2.5) and acetonitrile (volume 
ratio = 80:20); flow: 0.5 ml min–1.  
Figure 3. HPLC-chromatograms of crude NCav (top) and 
NSArg (bottom).Column: ZIC®-HILIC (100 × 4.6 mm); mo-
bile phase: mixture of 0.05 M CH3COONH4 (pH = 6.8) and 
acetonitrile (volume ratio = 50 : 50) for NCav, and mobile 
phase: mixture of 0.005 M CH3COONH4 (pH = 6.8) and 
acetonitrile (volume ratio = 20 : 80) for NsArg, respectively; 
flow: 0.5 ml min–1. 
Figure 4. Determination of chiral purity of NCav on a Risto-
cetin A phase. Column: 100 × 1 mm; mobile phase: mixture of 
0.1 % solution of TEAA in water (pH = 6.9) and methanol 
(volume ratio = 80 : 20); flow: 30 μl min–1.  
Table 1. Cytotoxicity of sulfo- and oxyguanidine arginine 
analogues in F4N cells 
Compound 
Cell growth inhibition(a) 
IC50(b) / mmol dm–3 
24 48 72 
NCav > 8 8 3.2 
NCav-CONHNHC6H5 > 8 2.5 1.3 
NsArg 4 3.3 2.4 
NsArg-CONHNHC6H5 4.6 1.7 0.8 
Cav(c) > 6 5.5 1.7 
CPH(c) 0.44 0.315 0.23 
(a) Exponentially growing cells were incubated in culture medium 
for 24, 48 and 72 h at 37 °C with varying amounts of the com-
pounds and counted thereafter hemocytometrically. The num-
ber of dead cells was determined by trypane blue exclusion. 
(b) Drug concentration that reduces the number of living cells 
by 50 %. Values are means of triplicate determination in at 
least two independent experiments. 
(c) Results from our previous research.10 
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firm our previous findings, showing that CPH was more 
cytotoxic than Cav by almost an order of magnitude.10 
NsArg ant its phenylhydrazide derivative exhibit higher 
cytotoxicity compared to the respective NCav com-
pounds. 
In conclusion, the main goal of the chemical ap-
proach applied was a quick and efficient preparation of 
NCav and NsArg of high purity, in a quantity sufficient 
for biological testing. That was achieved, since the 
HPLC data of the amino acid analogues revealed 95 % 
average purity, based on the relative peak area with 
monitoring at 230 and 254 nm. In addition 1 % of the 
unwanted enantiomer was detected. All tested com-
pounds showed cytotoxic activity against F4N cells. 
Phenylhydrazide derivatives proved to be more cyto- 
toxic than their parent compounds in accordance with 
our previous results.  
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